17
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Devices for endoscopic hemostasis of nonvariceal GI bleeding (with videos)

      other
      ASGE technology committee, , MD, MPH, FASGE 1 , , MD, MPH 2 , , MD, FASGE 3 , , MD, FASGE 4 , , MD 5 , , MD, FASGE 6 , , MD, FASGE 7 , , MD 8 , , MD, MPH, FASGE 9 , , MD, FASGE 10 , , MD 11 , , MD 12 , , MD 13 , , DO, FASGE 14 , , ASGE Technology Committee Chair
      VideoGIE
      Elsevier
      ABS, Ankaferd blood stopper, APC, argon plasma coagulation, ASGE, American Society for Gastrointestinal Endoscopy, CSEMS, covered self-expandable metallic stent, CPT, Current Procedural Terminology, EBL, endoscopic band ligation, EDP, endoscopic Doppler probe, U.S. FDA, United States Food and Drug Administration, GAVE, gastric antral vascular ectasia, HP, heater probe, LGIB, lower GI bleeding, MPEC, multipolar electrocoagulation, OTSC, over-the-scope clip, PTFE, polytetrafluoroethylene, RCT, randomized controlled trial, TTS, through-the-scope, UGIB, upper GI bleeding

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Endoscopic intervention is often the first line of therapy for GI nonvariceal bleeding. Although some of the devices and techniques used for this purpose have been well studied, others are relatively new, with few available outcomes data.

          Methods

          In this document, we review devices and techniques for endoscopic treatment of nonvariceal GI bleeding, the evidence regarding their efficacy and safety, and financial considerations for their use.

          Results

          Devices used for endoscopic hemostasis in the GI tract can be classified into injection devices (needles), thermal devices (multipolar/bipolar probes, hemostatic forceps, heater probe, argon plasma coagulation, radiofrequency ablation, and cryotherapy), mechanical devices (clips, suturing devices, banding devices, stents), and topical devices (hemostatic sprays).

          Conclusions

          Endoscopic evaluation and treatment remains a cornerstone in the management of nonvariceal upper- and lower-GI bleeding. A variety of devices is available for hemostasis of bleeding lesions in the GI tract. Other than injection therapy, which should not be used as monotherapy, there are few compelling data that strongly favor any one device over another. For endoscopists, the choice of a hemostatic device should depend on the type and location of the bleeding lesion, the availability of equipment and expertise, and the cost of the device.

          Related collections

          Most cited references113

          • Record: found
          • Abstract: found
          • Article: not found

          International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding.

          A multidisciplinary group of 34 experts from 15 countries developed this update and expansion of the recommendations on the management of acute nonvariceal upper gastrointestinal bleeding (UGIB) from 2003. The Appraisal of Guidelines for Research and Evaluation (AGREE) process and independent ethics protocols were used. Sources of data included original and published systematic reviews; randomized, controlled trials; and abstracts up to October 2008. Quality of evidence and strength of recommendations have been rated by using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) criteria. Recommendations emphasize early risk stratification, by using validated prognostic scales, and early endoscopy (within 24 hours). Endoscopic hemostasis remains indicated for high-risk lesions, whereas data support attempts to dislodge clots with hemostatic, pharmacologic, or combination treatment of the underlying stigmata. Clips or thermocoagulation, alone or with epinephrine injection, are effective methods; epinephrine injection alone is not recommended. Second-look endoscopy may be useful in selected high-risk patients but is not routinely recommended. Preendoscopy proton-pump inhibitor (PPI) therapy may downstage the lesion; intravenous high-dose PPI therapy after successful endoscopic hemostasis decreases both rebleeding and mortality in patients with high-risk stigmata. Although selected patients can be discharged promptly after endoscopy, high-risk patients should be hospitalized for at least 72 hours after endoscopic hemostasis. For patients with UGIB who require a nonsteroidal anti-inflammatory drug, a PPI with a cyclooxygenase-2 inhibitor is preferred to reduce rebleeding. Patients with UGIB who require secondary cardiovascular prophylaxis should start receiving acetylsalicylic acid (ASA) again as soon as cardiovascular risks outweigh gastrointestinal risks (usually within 7 days); ASA plus PPI therapy is preferred over clopidogrel alone to reduce rebleeding.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            ACG Clinical Guideline: Management of Patients With Acute Lower Gastrointestinal Bleeding.

            This guideline provides recommendations for the management of patients with acute overt lower gastrointestinal bleeding. Hemodynamic status should be initially assessed with intravascular volume resuscitation started as needed. Risk stratification based on clinical parameters should be performed to help distinguish patients at high- and low-risk of adverse outcomes. Hematochezia associated with hemodynamic instability may be indicative of an upper gastrointestinal (GI) bleeding source and thus warrants an upper endoscopy. In the majority of patients, colonoscopy should be the initial diagnostic procedure and should be performed within 24 h of patient presentation after adequate colon preparation. Endoscopic hemostasis therapy should be provided to patients with high-risk endoscopic stigmata of bleeding including active bleeding, non-bleeding visible vessel, or adherent clot. The endoscopic hemostasis modality used (mechanical, thermal, injection, or combination) is most often guided by the etiology of bleeding, access to the bleeding site, and endoscopist experience with the various hemostasis modalities. Repeat colonoscopy, with endoscopic hemostasis performed if indicated, should be considered for patients with evidence of recurrent bleeding. Radiographic interventions (tagged red blood cell scintigraphy, computed tomographic angiography, and angiography) should be considered in high-risk patients with ongoing bleeding who do not respond adequately to resuscitation and who are unlikely to tolerate bowel preparation and colonoscopy. Strategies to prevent recurrent bleeding should be considered. Nonsteroidal anti-inflammatory drug use should be avoided in patients with a history of acute lower GI bleeding, particularly if secondary to diverticulosis or angioectasia. Patients with established high-risk cardiovascular disease should not stop aspirin therapy (secondary prophylaxis) in the setting of lower GI bleeding. [corrected]. The exact timing depends on the severity of bleeding, perceived adequacy of hemostasis, and the risk of a thromboembolic event. Surgery for the prevention of recurrent lower gastrointestinal bleeding should be individualized, and the source of bleeding should be carefully localized before resection.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Bleeding peptic ulcer.

                Bookmark

                Author and article information

                Contributors
                Journal
                VideoGIE
                VideoGIE
                VideoGIE
                Elsevier
                2468-4481
                27 June 2019
                July 2019
                27 June 2019
                : 4
                : 7
                : 285-299
                Affiliations
                [1 ]Section for Gastroenterology & Hepatology, Tulane University Health Sciences Center, New Orleans, LA
                [2 ]Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI
                [3 ]Section of Digestive Diseases, Department of Internal Medicine, Yale University, New Haven, CT
                [4 ]Department of Gastroenterology, Hepatology and Nutrition, MD Anderson Cancer Center, The University of Texas, Houston, TX
                [5 ]Division of Gastroenterology, Department of Internal Medicine, Harvard Medical School and Massachusetts General Hospital, Boston, MA
                [6 ]Division of Gastroenterology, Boston Medical Center, Boston University School of Medicine, Boston, MA
                [7 ]Division of Digestive Diseases, Department of Internal Medicine, Rush University Medical Center, Chicago, IL
                [8 ]Center for Interventional Endoscopy, Florida Hospital, Orlando, FL
                [9 ]Division of Gastroenterology and Hepatology, Mayo Clinic Arizona, Scottsdale, AZ
                [10 ]Division of Digestive and Liver Diseases, New York-Presbyterian/Columbia University Medical Center, New York, NY
                [11 ]Division of Gastroenterology, University of Minnesota, Minneapolis, MN
                [12 ]Zucker School of Medicine at Hofstra/Northwell, Northwell Health System, New Hyde Park, NY
                [13 ]Interventional Endoscopy Services, California Pacific Medical Center, San Francisco, CA
                [14 ]Division of Digestive Diseases and Nutrition, University of Oklahoma Health Sciences Center, Oklahoma City, OK
                Author notes
                []Reprint requests: John T. Maple, DO, FASGE, ASGE Technology Committee Chair, 800 Stanton L Young Blvd, AAT 7400, Division of Digestive Diseases and Nutrition, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA. John-Maple@ 123456ouhsc.edu
                Article
                S2468-4481(19)30042-6
                10.1016/j.vgie.2019.02.004
                6616320
                31334417
                1452ca44-d50d-4a20-bf0b-5f2b72cd613e
                © 2019 by the American Society for Gastrointestinal Endoscopy. Published by Elsevier, Inc.

                This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

                History
                Categories
                Technology Assessment

                abs, ankaferd blood stopper,apc, argon plasma coagulation,asge, american society for gastrointestinal endoscopy,csems, covered self-expandable metallic stent,cpt, current procedural terminology,ebl, endoscopic band ligation,edp, endoscopic doppler probe,u.s. fda, united states food and drug administration,gave, gastric antral vascular ectasia,hp, heater probe,lgib, lower gi bleeding,mpec, multipolar electrocoagulation,otsc, over-the-scope clip,ptfe, polytetrafluoroethylene,rct, randomized controlled trial,tts, through-the-scope,ugib, upper gi bleeding

                Comments

                Comment on this article